Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis

IMPORTANCE: The optimum duration of adjuvant trastuzumab among patients with early breast cancer is uncertain but of great therapeutic relevance. OBJECTIVE: To compare shorter durations with 1 year of adjuvant trastuzumab for patients with early breast cancer. DATA SOURCES: PubMed, Embase, Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulia, Seema, Kannan, Sadhana, Badwe, Rajendra, Gupta, Sudeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445596/
https://www.ncbi.nlm.nih.gov/pubmed/32833018
http://dx.doi.org/10.1001/jamanetworkopen.2020.11777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445596/
https://www.ncbi.nlm.nih.gov/pubmed/32833018
http://dx.doi.org/10.1001/jamanetworkopen.2020.11777

Ejemplares similares